Want to see DRUG full AI Analyst Report?
DRUG Stock Chart & Stats
$79.49
$2.29(3.21%)
At close: 4:00 PM EDT
$79.49
$2.29(3.21%)
Day’s Range― - ―
52-Week Range$47.23 - $123.75
Previous Close$40.4
Volume103.68K
Average Volume (3M)132.89K
Market Cap
$497.54M
Enterprise Value$473.17M
Total Cash (Recent Filing)$308.33M
Total Debt (Recent Filing)$65.70K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Dec 17, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding9,864,061
10 Day Avg. Volume133,172
30 Day Avg. Volume132,886
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.08
Price to Sales (P/S)0.00
P/FCF Ratio-66.82
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.80K
Enterprise Value/Ebitda-13.94
Forecast
1Y Price Target
$165.25Price Target Upside107.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.5
Revenue Forecast (FY)$25.45M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces refinancing pressure and fixed financial obligations while preserving flexibility to direct capital toward research and development. This gives Bright Minds a less leveraged balance sheet than many development-stage companies, although it does not eliminate the need to fund ongoing losses.
Larger Equity BaseThe substantially larger equity base strengthens the company’s funding position and suggests a broader capital cushion for advancing its pipeline. That added financial capacity can support clinical and preclinical work over the medium term, even though continued losses may consume part of it.
Shareholder Governance SupportStrong shareholder approval of the full board and near-unanimous auditor approval indicate continuity in governance and oversight. Stable backing can help management maintain focus on the development pipeline and may support stakeholder confidence as the company progresses through a capital-intensive stage.
Bears Say
No Operating RevenueWith no reported product revenue, Bright Minds lacks an operating base to fund research, clinical trials, or corporate costs internally. The business therefore remains dependent on financing or future partnering and commercialization success, making execution and access to capital central to its medium-term outlook.
Widening LossesLosses have expanded materially while EBIT remains deeply negative, showing that current spending is not being supported by operating income. Persistent and widening deficits can erode the equity base over time and increase the amount of external capital required to advance the company’s candidates.
Accelerating Cash BurnThe sharp increase in operating cash burn indicates rising funding needs as development activity and operating expenses intensify. Because free cash flow is also negative in every period shown, Bright Minds has limited internal cash generation and may need additional financing to sustain its pipeline.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $47.23 and its highest was $123.75 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is $497.54M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Dec 17, 2026 which is in 54 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.173 earnings per share for the quarter, beating the consensus estimate of -$1.283 by $1.11.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.16.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,864,061 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.173 in its last earnings report, beating expectations of -$1.283. Following the earnings report the stock price went up 3.977%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
DRUG Stock 12 Month Forecast
Average Price Target
$165.25
▲(107.89% Upside)
Technical Analysis
Ownership Overview
20.48% Insiders
4.37% Mutual Funds
<0.01% Other Institutional Investors
70.38% Public Companies and
Individual Investors